{
    "doi": "https://doi.org/10.1182/blood.V108.11.2678.2678",
    "article_title": "Treatment of Myelodysplastic Syndromes with del 5q before the Lenalidomide Era: The GFM Experience. ",
    "article_date": "November 16, 2006",
    "session_type": "Poster Sessions",
    "abstract_text": "Background: MDS with del 5q are characterized by profound anemia, which until the recent introduction of lenalidomide ( N Engl J Med  2005 ; 352 : 549 \u201357 , J Clin Oncol  2005 ; 16S : 5 ), was considered generally unresponsive to available treatments. In order to reevaluate the outcome of those patients in the pre-lenalidomide era, we analyzed response of anemia in MDS with del 5q treated with EPO \u00b1 G-CSF and thalidomide in previous GFM trials. Patients: MDS with del 5q included in 419 MDS treated with EPO or Darbepoetin (DAR) \u00b1 G-CSF by GFM centers (including 3 successive GFM trials: Blood  2004 ; 104 : 321 \u20137 ; Blood  2005 ; 106 suppl 1: 712a ; Br J Haematol  2006 ; 133 : 513 \u20139 and submitted to ASH 2006), and in 134 MDS treated with thalidomide in two successive GFM trials ( Br J Haematol  2005 ; 131 : 609 \u201318 , and submitted to ASH 2006). Patients received at least 30,000 U/w of EPO or 300 mg/w of DAR and doses ranging from 50 to 800 mg/d of Thalidomide during at least 12 weeks. Results: 48 MDS with del 5q received EPO (or DAR) \u00b1 G-CSF, including 30 pts with del 5q alone, 9 with one and 9 with >1 additional cytogenetic abn; 21/48 had marrow blasts \u22655% (7 had >10%). 17 had the \u201c5q- syndrome\u201d according to WHO. Median pre-treatment EPO level was 287 UI/L (range 12\u20135,665), i.e. significantly more than in non del 5q cases (median 68, p1 additional cytogenetic abn, and marrow blasts \u22655%. Response duration was significantly shorter in MDS with del 5q than in other MDS (mean 12 vs. 24 months, p=0.019) and in pts with 5q- syndrome vs. other MDS with marrow blasts <5% (mean 11vs. 24months, p=0.025). 20 pts with del 5q were treated with thalidomide. 6/20 had an erythroid response (30 %, including 3 major and 3 minor responses) vs. 29% of other MDS (p=NS) Conclusion: MDS with del 5q with \u22641 additional cytogenetic abn and no excess of marrow blasts may have erythroid response to EPO \u00b1 G-CSF but responses are generally very short, while response rates to thalidomide are low. Those results are clearly inferior to results obtained with lenalidomide in MDS with del 5q.",
    "topics": [
        "lenalidomide",
        "myelodysplastic syndrome",
        "brachial plexus neuritis",
        "granulocyte colony-stimulating factor",
        "recombinant granulocyte colony stimulating factor",
        "thalidomide",
        "5q syndrome",
        "anemia",
        "frequency of responses",
        "blast cells"
    ],
    "author_names": [
        "Charikleia Kelaidi, MD",
        "Sophie Park, MD",
        "Sabine Brechignac, MD",
        "Lionel Mannone, MD",
        "Norbert Vey, MD",
        "Herve Dombret, MD",
        "Lina Aljassem, MD",
        "Aspasia Stamatoullas, MD",
        "Lionel Ade\u0300s, MD",
        "Ste\u0301phane Giraudier, MD",
        "Ste\u0301phane de Botton, MD",
        "Be\u0301atrice Mahe\u0301, MD",
        "Pascale Lepelley, MD",
        "Franc\u0327oise Picard, MD",
        "Genevie\u0300ve Leroux, MD",
        "Marie-The\u0301re\u0300se Daniel, MD",
        "Didier Bouscary, MD",
        "Franc\u0327ois Dreyfus, MD",
        "Pierre Fenaux, MD"
    ],
    "author_dict_list": [
        {
            "author_name": "Charikleia Kelaidi, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 1,
            "first_author": 1,
            "last_author": 0
        },
        {
            "author_name": "Sophie Park, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 2,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Sabine Brechignac, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 3,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lionel Mannone, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 4,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Norbert Vey, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 5,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Herve Dombret, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 6,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lina Aljassem, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 7,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Aspasia Stamatoullas, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 8,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Lionel Ade\u0300s, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 9,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ste\u0301phane Giraudier, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 10,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Ste\u0301phane de Botton, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 11,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Be\u0301atrice Mahe\u0301, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 12,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pascale Lepelley, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 13,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Franc\u0327oise Picard, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 14,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Genevie\u0300ve Leroux, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 15,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Marie-The\u0301re\u0300se Daniel, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 16,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Didier Bouscary, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 17,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Franc\u0327ois Dreyfus, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 18,
            "first_author": 0,
            "last_author": 0
        },
        {
            "author_name": "Pierre Fenaux, MD",
            "author_affiliations": [
                "Groupe Francophone des Myelodysplasies, He\u0301matologie Clinique, Bobigny, France"
            ],
            "author_rank": 19,
            "first_author": 0,
            "last_author": 1
        }
    ],
    "datetime_abstract_obtained": "2022-05-01T02:51:33",
    "is_scraped": "1"
}